Clinical Trial Update: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating bemarituzumab with modified FOLFOX6 in gastric/gastroesophageal junction cancer has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Bemarituzumab (bemarituzumab)
• Modified FOLFOX6 (FOLFOX6 regimen)

Snippet

Sponsor: Five Prime Therapeutics, Inc. | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-05-24